Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALA-CORT vs BRICANYL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Beta-2 adrenergic receptor agonist; stimulates adenyl cyclase, increasing cyclic AMP, leading to bronchodilation.
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (FDA),Off-label: Atopic dermatitis, psoriasis, contact dermatitis, lichen planus, discoid lupus erythematosus
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease,Acute asthma exacerbation,Off-label: Management of acute hyperkalemia,Off-label: Prevention of preterm labor (terbutaline)
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
Subcutaneous: 0.25-0.5 mg every 1-2 hours as needed; Intravenous: 0.25-0.5 mg over 1 minute, may repeat every 1-2 hours; Inhalation (metered-dose inhaler): 2 inhalations (0.4 mg) every 6 hours; Nebulized: 2.5-5 mg every 6-8 hours.
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
3-4 hours (terminal); prolonged in renal impairment (up to 8-10 hours) and in elderly patients.
Topically applied; systemic absorption is minimal but can be increased with use on large areas, occlusive dressings, or damaged skin. Absorbed portion is metabolized primarily in the liver via hepatic microsomal enzymes (CYP3A4) and excreted by the kidneys.
Metabolized in the liver via sulfonation (sulfotransferase enzymes) and to a minor extent by catechol-O-methyltransferase (COMT).
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Primarily renal (60-70% as unchanged drug and metabolites); fecal elimination accounts for a minor fraction (<5%).
Hydrocortisone is approximately 90–95% bound to corticosteroid-binding globulin (CBG, transcortin) and albumin.
Approximately 25% bound to albumin.
Apparent volume of distribution (Vd) is approximately 0.4–0.6 L/kg, indicating moderate tissue distribution and limited penetration into CNS.
~0.6 L/kg; indicates distribution into total body water.
Topical: Bioavailability is negligible (<1%) through intact skin; may increase (up to 30%) with damaged skin or occlusive dressings. Rectal: Bioavailability is approximately 10–20% via mucosal absorption, with first-pass metabolism reducing systemic exposure.
Inhalation: ~10-20% (dependent on device and technique); Oral: ~15-20% (due to extensive first-pass metabolism).
No adjustment required for topical use; systemic absorption minimal.
No specific dose adjustment recommended for renal impairment; use with caution in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to potential for increased systemic exposure.
No adjustment required for topical use; hepatic metabolism negligible.
No specific dose adjustment recommended; caution in severe hepatic impairment (Child-Pugh Class C) due to reduced clearance.
Children ≥2 years: Apply a thin film to affected area 2-3 times daily. Use lowest potency preparation; avoid prolonged use.
Subcutaneous: 5-10 mcg/kg every 1-2 hours as needed (max 0.5 mg); Intravenous: 5-10 mcg/kg over 1 minute (max 0.5 mg); Inhalation (MDI): 1-2 inhalations (0.2-0.4 mg) every 4-6 hours; Nebulized: 0.01-0.03 mg/kg (max 1 mg) every 6-8 hours.
Use lowest effective dose; monitor for skin atrophy and systemic effects due to thinner skin and increased percutaneous absorption.
Initiate at lower end of dosing range (e.g., subcutaneous 0.125 mg); monitor for tachycardia, hypertension, and tremor; consider age-related decline in renal and hepatic function.
None
Not available
Systemic absorption may cause reversible HPA axis suppression,Cushing's syndrome, hyperglycemia, and glucosuria with prolonged use,Local adverse reactions: atrophy, striae, telangiectasias, acneiform eruptions, perioral dermatitis,May mask signs of infection,Use with caution in pediatric patients due to increased susceptibility to HPA axis suppression,Avoid use on face, intertriginous areas, and under occlusive dressings unless directed by physician
Paradoxical bronchospasm may occur,Cardiovascular effects (e.g., tachycardia, arrhythmias, increased blood pressure) use caution with cardiovascular disorders,Hypokalemia may occur,Hyperglycemia reported,Immediate hypersensitivity reactions
Hypersensitivity to any component of the formulation,Untreated bacterial, viral, fungal, or parasitic skin infections,Viral skin infections (e.g., herpes simplex, varicella) at treatment site,Perioral dermatitis,Rosacea
Hypersensitivity to any component,Tachydysrhythmias,Cardiac glycoside toxicity with arrhythmias
No known food interactions with topical ALA-CORT.
No significant food interactions. However, avoid excessive caffeine intake (coffee, tea, cola) as it may exacerbate beta-agonist side effects like palpitations and tremor.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restriction, adrenal suppression in fetus. Avoid prolonged use.
Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if clearly needed. First trimester: limited data suggest no major malformations. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and transient hypocalcemia. Avoid in preterm labor due to maternal and fetal adverse effects.
Provides small amounts in breast milk; M/P ratio unknown. At maternal doses up to 80 mg/day, no adverse effects reported in infants. Consider risk-benefit with high doses or prolonged therapy.
Excreted into breast milk in small amounts; M/P ratio approximately 2.5. No adverse effects reported in infants at therapeutic maternal doses. However, monitor infant for signs of beta-2 adrenergic stimulation (e.g., tachycardia, irritability). Consider risk-benefit.
Pregnancy-induced pharmacokinetic changes (increased clearance, volume of distribution) may require increased dosing, but clinical response should guide adjustment. Avoid high doses and prolonged use.
No specific dose adjustments recommended for asthma or COPD. However, in preterm labor (off-label), use lowest effective dose and shortest duration due to increased risk of maternal pulmonary edema, cardiac ischemia, and fetal effects. Monitor closely.
ALA-CORT (hydrocortisone acetate 2.5% and pramoxine HCl 1%) is a topical corticosteroid with anesthetic. Use for short-term relief of pruritus and inflammation in corticosteroid-responsive dermatoses. Avoid prolonged use on intertriginous or occluded areas. Limit to <2 weeks continuous use in adults to avoid skin atrophy. Not recommended for children <2 years.
BRICANYL (terbutaline sulfate) is a beta-2 adrenergic agonist used for bronchodilation in asthma and COPD. It can cause transient hypokalemia, hyperglycemia, and tremor. Use with caution in patients with diabetes, hypertension, or hyperthyroidism. Monitor serum potassium in patients on diuretics or with hypoxia. Not recommended for acute severe asthma as monotherapy; prefer short-acting beta-agonists like albuterol.
Apply a thin layer to affected area no more than 3-4 times daily.,Do not cover with bandages or plastic unless directed by doctor.,Avoid contact with eyes, mouth, or broken skin.,Discontinue and notify doctor if infection, irritation, or no improvement after 7 days.,Do not use for diaper dermatitis or under diapers/occlusive dressings.,Keep out of reach of children.
Use exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Shake the inhaler well before each use.,Rinse mouth with water after inhalation to prevent oral thrush.,Seek emergency medical help if breathing problems worsen or if you have chest pain or irregular heartbeat.,Monitor blood sugar if diabetic as this medication may raise blood glucose levels.,Avoid caffeine as it may increase side effects like nervousness and rapid heart rate.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALA-CORT vs BRICANYL, answered by our medical review team.
ALA-CORT is a Topical Corticosteroid that works by Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.. BRICANYL is a Beta-2 Agonist that works by Beta-2 adrenergic receptor agonist; stimulates adenyl cyclase, increasing cyclic AMP, leading to bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALA-CORT and BRICANYL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALA-CORT is: Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.. The standard adult dose of BRICANYL is: Subcutaneous: 0.25-0.5 mg every 1-2 hours as needed; Intravenous: 0.25-0.5 mg over 1 minute, may repeat every 1-2 hours; Inhalation (metered-dose inhaler): 2 inhalations (0.4 mg) every 6 hours; Nebulized: 2.5-5 mg every 6-8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALA-CORT and BRICANYL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALA-CORT is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restri. BRICANYL is classified as Category C. Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if clearly needed. First trimester: limit. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.